

REMARKS

The Requirement for Restriction was directed to claims 1-26 which have been cancelled without prejudice. New claims 27-48 are presented herein for the Examiner's consideration. Entry of new claims 27-48 is respectfully requested. Upon entry of this Amendment new claims 27-48 will be pending in the present application.

No new matter is introduced by this Amendment. Support for new claims 27-48 is found throughout the specification. Applicant points out that all of new claims 27-48 are directed, *inter alia*, to methods of using bioactive material to abrade human or animal tissue. Accordingly, all of the new claims appear to fit within what the Examiner designated as Group II in the Official Action. As noted by the Examiner, "Group II is drawn to a method of using the product." Likewise, new claims 27-48 are directed to such methods.

In the Official Action the Examiner required the election of a single species of bioactive material. In response, applicant elects the single species "bioactive glass."

In view of the foregoing, withdrawal of the requirement for restriction is respectfully requested and an early action on the merits on new claims 27-48 is courteously solicited. In the event that the Examiner has any questions concerning this Amendment and Response to Restriction Requirement, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application may be expedited.

No fees are believed due in connection with the filing of this Amendment and Response to Restriction Requirement. However, the Director is hereby authorized to charge any required fees and credit any overpayments to Deposit Account No. 50-0540.

Respectfully submitted,

Dated: February 7, 2007

/Robert E. Alderson/

Robert E. Alderson, Reg. No. 44,500
Attorney for Applicant
KRAMER LEVIN NAFTALIS & FRANKEL LLP
1177 Avenue of the Americas
New York, New York 10036
(212) 715-9100 (phone)
(212) 715-8000 (fax)